Assistant Professor of Neurology, Dana-Farber Cancer Institute
Neurology
Dr. Andrew D. Norden, MD
|
|
Give Review
Andrew Norden is an expert in the field of Neurology. He researched medicine at Yale University School of Medicine. Yale University School of Medicine is one of the top medical schools in the US. Yale University School of Medicine has a rank of 7 in research and a 57 in primary care Dr. Andrew D. Norden is a published physician as well. He has 47 publications published. The latest was: A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. He is registered with Medicare.
Publications
- Central Nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
- A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with Gliomas undergoing radiotherapy.
- A prognostic cytogenetic scoring System to guide the adjuvant management of patients with atypical meningioma.
- Epilepsy in glioma patients: mechanisms, management, and impact of anticonvulsant therapy.
- Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma.
- Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
- Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
- Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
- Welcoming the era of quality improvement in neuro-oncology.
- Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
- Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade Gliomas.
- Medical management of Brain tumors and the sequelae of treatment.
- Antiangiogenic therapies for glioblastoma.
- Retrospective study of using carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab.
- Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
- Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study.
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
- Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survival.
- Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevac...
- Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
- DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues.
- Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis.
- Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma.
- Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients.
- Survival among patients with primary central Nervous system lymphoma, 1973-2004.
- Longitudinal MRI evidence for decreased survival among periventricular glioblastoma.
- Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.
- Medical therapies for Meningiomas.
- Recurrent high-grade glioma.
- Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma.
- Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
- Response assessment challenges in clinical trials of Gliomas.
- Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
- Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab.
- Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression.
- Antiangiogenic strategies for treatment of malignant Gliomas.
- Advances in meningioma therapy.
- Colon perforation during antiangiogenic therapy for malignant glioma.
- A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiforme.
- Phase II study of protracted daily temozolomide for low-grade Gliomas in adults.
- Antiangiogenic therapy in malignant Gliomas.
- Medical management of Brain tumor patients.
- Targeted drug therapy for Meningiomas.
- Glioma therapy in adults.
- Positive and negative network correlations in temporal lobe Epilepsy.
- The role of subcortical structures in human Epilepsy.
Schools
Yale University School Of Medicine
Brigham and Women39s Hospital
Bwh and Mass General Hospital
Mgh and Dana Farber Cancer Insti
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Autonomic Disorders
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Education
-
Brigham and Women's Hospital -
Yale University School of Medicine
Hospital
-
Boston Children's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute -
South Shore Hospital -
Brigham and Women's Hospital
Drug Facts
| NPI NUMBER | 1497737456 | |
| NPPES Provider LastName | NORDEN | |
| NPPES Provider FirstName | ANDREW | |
| NPPES Provider ZIPCode | 022155418 | |
| NPPES Provider State | MA | |
| Specialty Description | Neurology | |
| Total Claim Count | 105.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1497737456 |
| Last Name Of The Provider | NORDEN |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
|
Dr. Catherine L. Leveroni, PHD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John R. Sims, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard R. Darby III, MD |
|
|
Dr. Christine A. Cooper, MD |
|
|
Dr. Gregory J. Allam, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Michael P. Bowley, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alice W. Flaherty, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Janet L. Jankowiak, MD |
|
|
Simy R. Kabaria |